Medivation, Inc. (MDVN) exercised its option to gain exclusive worldwide rights to pidilizumab (CT-011) from CureTech, Ltd. under the terms of the license agreement entered into on Oct 23, 2014. Per ...

JERUSALEM, Sep 13, 2011 (BUSINESS WIRE) -- -- Investment Follows Positive Phase II Results in Lymphoma -- Teva Pharmaceutical Industries Ltd. /quotes/zigman/64731 ...

SAN FRANCISCO, CA and YAVNE, ISRAEL--(Marketwired - Oct 23, 2014) - Medivation, Inc. (NASDAQ: MDVN) and CureTech, Ltd. today announced Medivation has licensed exclusive worldwide rights to CureTech's ...

-- Achieved Statistically Significant Results in Secondary Endpoint of Overall Survival -- JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and CureTech, a portfolio ...

CT-011 Was Well Tolerated with No Treatment Related Toxicities; Clinical Responses Were Observed in Several Patients Seven to Eight Months Post Treatment CureTech Ltd, a biotechnology company focused ...

Israeli drugmaker Teva Pharmaceutical Industries has invested $19 million in CureTech equity on the strength of Phase II trial results with CT-011, their partnered drug for B cell lymphoma. Israeli ...

Teva Pharmaceutical Industries said today it ended a nearly seven-year collaboration with CureTech on the humanized monoclonal antibody CT-011 being for blood malignancies and solid tumors, after ...

"We are in the process of conducting a disciplined review of our pipeline. As we looked closely at CT-011 and the most recent clinical and biochemical data, we have made the strategic decision to ...

Teva Pharmaceutical Industries Ltd. and CureTech, a portfolio company of Teva and Clal Biotechnology Industries announced preliminary topline results for CT-011, an investigational anti-PD-1 ...

JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today its decision to exercise its option to make an additional $19 million investment in CureTech Ltd., and ...